Persistence, effectiveness and safety of dabigatran in “real-world” Chinese patients with nonvalvular atrial fibrillation

In conclusion, it is of importance for Chinese clinicians to know about these information because dabigatran is a relatively new drug in China. Compared with other reported data, patients of this study have (1) lower dabigatran persistence and lower incident rates of all-cause death, systemic embolism, minor bleeding events and gastrointestinal hemorrhage and (2) higher incident rates of ischemic stroke and intracranial hemorrhage.

Source: Heart and Vessels - January 30, 2020 Category: Cardiology Source Type: research